Role of remnant lipoprotein cholesterol in the management of blood lipid

doi:10.3969/j.issn.1673-8640.2019.05.003

Abstract

Abstract:

Objective To investigate the role of remnant lipoprotein cholesterol （RLP-C） in the management of blood lipid and the correlation between RLP-C and cardiovascular disease（CVD） associated biomarkers. Methods Serum levels of RLP-C,glucose （Glu）,triglyceride （TG）,total cholesterol （TC）,low-density lipoprotein cholesterol （LDL-C）,high-density lipoprotein cholesterol （HDL-C）,small-density low-density lipoprotein cholesterol （sd-LDL-C）,apolipoprotein （apo） A1, apo B,lipoprotein（a） [Lp（a）],lipoprotein-associated phospholipase A₂ （Lp-PLA₂） and C-reactive protein （CRP） of 437 healthy subjects were determined. The levels of RLP-C determined directly were marked RLP-C-m, and those calculated were marked RLP-C-calc,and non-HDL-C was calculated. Correlation analysis and stratified analysis were used to investigate the correlation and discrepancy between RLP-C and other CVD associated biomarkers and the influence of methodology on the level of RLP-C acquired. Results There was statistical significance in biomarkers between females and males,except ages,Glu,LDL-C,sd-LDL-C and Lp-PLA₂ （P<0.05）. The correlations between RLP-C and ages,Glu,HDL-C,apo A1,Lp（a）,Lp-PLA₂ and CRP were relatively weak with small r （P<0.05）. RLP-C-m and RLP-C-calc were positively correlated with non-HDL-C,TC,TG,LDL-C,apo B and sd-LDL-C （P<0.001）. RLP-C-m was positively correlated with TG （r=0.899,P<0.001）. RLP-C-calc and non-HDL-C were strongly and positively correlated with TC（P<0.001）,and RLP-C-m was positively correlated with RLP-C-calc and non-HDL-C （P<0.001）. The RLP-C-m level was elevated with the increase of RLP-C-calc,but it was constantly lower than RLP-C-calc. The 437 healthy subjects were stratified according to the levels of TG （<1.00,1.00-1.99,2.00-2.99 and ≥3.00 mmol/L）. The levels of RLP-C-m,RLP-C-calc, non-HDL-C, TC,sd-LDL-C and RLP-C-m were elevated with the increase of TG. The analysis of variance（ANOVA） suggested that,among the biomarkers,RLP-C-m and RLP-C-calc showed statistical significance among all the groups （P<0.001）. Conclusions RLP-C is a constant biomarker with strong and positive correlation with TG. The levels of RLP-C determined by different methods differs from each other, but they are correlated. The determination of RLP-C might help blood lipid management and risk control in CVD patients,but further researches are required to regard it as an independent factor for predicting CVD risk.

Key words: Remnant lipoprotein cholesterol, Triglyceride-rich lipoprotein, Blood lipid management, Cardiovascular disease

CLC Number:

R446.1

SONG Yunxiao, GE Wen, ZHANG Haichen, YUAN Wenhua, DAI Jun, YOU Wenshi. Role of remnant lipoprotein cholesterol in the management of blood lipid[J]. Laboratory Medicine, 2019, 34(5): 394-400.

Figures/Tables 5

References 21

[1]	TWICKLER T B,DALLINGA-THIE G M,COHN J S,et al. Elevated remnant-like particle cholesterol concentration:a characteristic feature of the atherogenic lipoprotein phenotype[J]. Circulation,2004,109(16):1918-1925.
[2]	COHN J S,MARCOUX C,DAVIGNON J.Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins[J]. Arterioscler Thromb Vasc Biol,1999,19(10):2474-2486.
[3]	JIALAI I,DEVARAJ S.Remnant lipoproteins: measurement and clinical significance[J]. Clin Chem,2002,48(2):217-219.
[4]	ZILVERSMIT D B.Atherogenic nature of triglycerides, postprandial lipemia, and triglyceride-rich remnant lipoproteins[J]. Clin Chem,1995,41(1):153-158.
[5]	MCNAMARA J R,SHAN P K,NAKAJIMA K,et al.Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study[J]. Clin Chem,1998,44(6 Pt 1):1224-1232.
[6]	VARBO A,NORDESTGAARD B G.Remnant cholesterol and triglyceride-rich lipoproteins in atherosclerosis progression and cardiovascular disease[J]. Arterioscler Thromb Vasc Biol,2016,36(11):2133-2135.
[7]	SAEED A,FEOFANOVA E V,YU B,et al.Remnant-like particle cholesterol, low-density lipoprotein triglycerides, and incident cardiovascular disease[J]. J Am Coll Cardiol,2018,72(2):156-169.
[8]	VALLEJO-VAZ A J,FAYYAD R,BOEKHOLDT S M,et al. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial[J]. Circulation,2018,138(8):770-781.
[9]	VARBO A,FREIBERG J J,NORDESTGAARD B G,et al.Remnant cholesterol and myocardial infraction in normal weight, overweight, and obese individuals from the Copenhagen general population study[J]. Clin Chem,2018,64(1):219-230.
[10]	JEPSEN A M,LANGSTED A,VARBO A,et al.Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5 414 patients with ischemic heart disease[J]. Clin Chem,2016,62(4):593-604.
[11]	Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program(NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults(Adult Treatment Panel Ⅲ)[J]. JAMA,2001,285(19):2486-2497.
[12]	TERAMOTO T,SASAKI J,ISHIBASHI S,et al.Cardiovascular disease risk factors other than dyslipidemia Executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan-2012 version[J]. J Atheroscler Thromb,2013,20(10):733-742.
[13]	中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志,2016,31(10):937-950.
[14]	ASSMANN G,SCHULTE H.Relation of high-density liporotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease(the PROCAM experience). Prospective cardiovascular münster study[J]. Am J Cardiol,1992,70(7):733-737.
[15]	CHAN D C,WATTS G F,BARRETT P H,et al.Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity[J]. Clin Chem,2002,48(2):278-283.
[16]	MASUOKA H,KAMEI S,OZAKI M,et al.Predictive value of remnant-like particle cholesterol as an indicator of coronary artery stenosis in patients with normal serum triglyceride levels[J]. Intern Med,2000,39(7):540-546.
[17]	NAKADA Y,KUROSAWA Y,TOHYAMA J,et al.Increased remnant lipoprotein in patients with coronary artery disease-evaluation utilizing a newly developed remnant assay, remnant lipoprotein cholesterol homogenous assay(RemL-C)[J]. J Atheroscler Thromb,2007,14(2):56-64.
[18]	YOSHIDA H,KUROSAWA H,HIROWATARI Y,et al.Characteristic comparison of triglyceride-rich remnant lipoprotein measurement between a new homogenous assay(RemL-C) and a conventional immunoseparation method(RLP-C)[J]. Lipids Health Dis,2008,7:18.
[19]	MCNAMARA J R,SHAH P K,NAKAJIMA K,et al.Remnant-like particle(RLP) cholesterol is an independent cardiovascular disease risk factor in women:results from the Framingham Heart Study[J]. Atherosclerosis,2001,154(1):229-236.
[20]	VARBO A,NORDESTGAARD B G.Remnant lipoproteins[J]. Curr Opin Lipidol,2017,28(4):300-307.
[21]	IMKE C,RODRIGUEZ B L,GROVE J S,et al.Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu heart study[J]. Atheroscler Thromb Vasc Biol,2005,25(8):1718-1722.

组别	例数	年龄（岁）	Glu（U/L）	TC（mmol/L）	TG（mmol/L）	HDL-C（mmol/L）
男性	228	72（62~85）	5.94（4.82~6.37）	4.28±1.08	1.25（0.86~1.77）	0.99（0.83~1.23）
女性	209	77（65~85）	5.96（4.69~6.32）	4.69±1.09^***	1.39（0.91~1.97）^***	1.13（0.95~1.43）^***
合计	437	74（64~85）	5.95（4.74~6.36）	4.47±1.11	1.32（0.88~1.89）	1.05（0.89~1.30）
组别	LDL-C（mmol/L）		non-HDL-C（mmol/L）	apo A1（g/L）	apo B（g/L）	Lp（a）（g/L）
男性	2.30（1.77~2.61）		3.23±1.05	1.17±0.21	0.86±0.30	0.23（0.13~0.38）
女性	2.30（1.93~2.81）		3.48±1.01^*	1.32±0.23^***	0.92±0.29^*	0.27（0.17~0.40）^*
合计	2.30（1.88~2.71）		3.35±1.04	1.24±0.23	0.89±0.29	0.24（0.15~0.39）
组别	sd-LDL-C（mmol/L）		RLP-C-m（mmol/L）	RLP-C-calc（mmol/L）	Lp-PLA2（U/L）	CRP（mg/L）
男性	0.46（0.36~0.63）		0.21（0.13~0.33）	0.90（0.66~1.15）	439（341~548）	2.25（0.80~10.55）

组别	例数	年龄（岁）	Glu（U/L）	TC（mmol/L）	TG（mmol/L）	HDL-C（mmol/L）
男性	228	72（62~85）	5.94（4.82~6.37）	4.28±1.08	1.25（0.86~1.77）	0.99（0.83~1.23）
女性	209	77（65~85）	5.96（4.69~6.32）	4.69±1.09^***	1.39（0.91~1.97）^***	1.13（0.95~1.43）^***
合计	437	74（64~85）	5.95（4.74~6.36）	4.47±1.11	1.32（0.88~1.89）	1.05（0.89~1.30）
组别	LDL-C（mmol/L）		non-HDL-C（mmol/L）	apo A1（g/L）	apo B（g/L）	Lp（a）（g/L）
男性	2.30（1.77~2.61）		3.23±1.05	1.17±0.21	0.86±0.30	0.23（0.13~0.38）
女性	2.30（1.93~2.81）		3.48±1.01^*	1.32±0.23^***	0.92±0.29^*	0.27（0.17~0.40）^*
合计	2.30（1.88~2.71）		3.35±1.04	1.24±0.23	0.89±0.29	0.24（0.15~0.39）
组别	sd-LDL-C（mmol/L）		RLP-C-m（mmol/L）	RLP-C-calc（mmol/L）	Lp-PLA2（U/L）	CRP（mg/L）
男性	0.46（0.36~0.63）		0.21（0.13~0.33）	0.90（0.66~1.15）	439（341~548）	2.25（0.80~10.55）

指标	RLP-C-m	RLP-C-calc	non-HDL-C	TC	TG	HDL-C	LDL-C	sd-LDL-C	Lp-PLA₂
RLP-C-m		0.687^***	0.623^***	0.486^***	0.899^***	-0.280^***	0.460^***	0.649^***	0.286^***
RLP-C-calc			0.809^***	0.745^***	0.585^***	-0.014	0.557^***	0.615^***	0.358^***
non-HDL-C				0.947^***	0.455^***	0.039	0.922^***	0.679^***	0.509^***
TC					0.282^***	0.340^***	0.881^***	0.618^***	0.444^***
TG						-0.437^***	0.285^***	0.581^***	0.164^***
HDL-C							0.088	-0.067	-0.090
LDL-C								0.566^***	0.498^***
sd-LDL-C									0.378^***
年龄	-0.136^**	-0.139^**	-0.207^**	-0.179^**	-0.120^*	0.013	-0.223^**	-0.165^**	-0.026
Glu	0.170^**	0.148^**	0.083	0.016	0.276^**	-0.200^**	0.017	0.235^**	0.008
apo A1	0.052	0.207^**	0.200	0.463^**	-0.090^*	0.869^**	0.186^**	0.183^**	-0.029
apo B	0.483^**	0.679^**	0.914^**	0.856^**	0.357^**	0.028	0.923^**	0.589^**	0.510**
Lp（a）	-0.102^*	0.028	0.091	0.118^*	-0.091	0.076	0.134^**	-0.081	0.031
CRP	-0.172^**	-0.079^**	-0.053	-0.102^*	-0.107^*	-0.213^**	-0.034	-0.146^**	0.014

指标	RLP-C-m	RLP-C-calc	non-HDL-C	TC	TG	HDL-C	LDL-C	sd-LDL-C	Lp-PLA₂
RLP-C-m		0.687^***	0.623^***	0.486^***	0.899^***	-0.280^***	0.460^***	0.649^***	0.286^***
RLP-C-calc			0.809^***	0.745^***	0.585^***	-0.014	0.557^***	0.615^***	0.358^***
non-HDL-C				0.947^***	0.455^***	0.039	0.922^***	0.679^***	0.509^***
TC					0.282^***	0.340^***	0.881^***	0.618^***	0.444^***
TG						-0.437^***	0.285^***	0.581^***	0.164^***
HDL-C							0.088	-0.067	-0.090
LDL-C								0.566^***	0.498^***
sd-LDL-C									0.378^***
年龄	-0.136^**	-0.139^**	-0.207^**	-0.179^**	-0.120^*	0.013	-0.223^**	-0.165^**	-0.026
Glu	0.170^**	0.148^**	0.083	0.016	0.276^**	-0.200^**	0.017	0.235^**	0.008
apo A1	0.052	0.207^**	0.200	0.463^**	-0.090^*	0.869^**	0.186^**	0.183^**	-0.029
apo B	0.483^**	0.679^**	0.914^**	0.856^**	0.357^**	0.028	0.923^**	0.589^**	0.510**
Lp（a）	-0.102^*	0.028	0.091	0.118^*	-0.091	0.076	0.134^**	-0.081	0.031
CRP	-0.172^**	-0.079^**	-0.053	-0.102^*	-0.107^*	-0.213^**	-0.034	-0.146^**	0.014

组别	例数	TC（mmol/L）	HDL-C（mmol/L）	LDL-C（mmol/L）
TG<1.00 mmol/L组	136	4.12±1.13	1.28（1.01~1.58）	2.06±0.71^***
TG 1.00~1.99 mmol/L组	209	4.48±1.04^*	1.04（0.90~1.24）^***	2.43±0.77^***
TG 2.00~2.99 mmol/L组	57	4.86±1.07^***	0.99（0.79~1.09）^***	2.62±0.74^***
TG≥3.00 mmol/L组	35	5.20±0.94^***#	0.85（0.76~0.97）^***##	2.53±0.57^**
组别	sd-LDL-C（mmol/L）		RLP-C-calc（mmol/L）	RLP-C-m（mmol/L）	non-HDL-C（mmol/L）
TG<1.00 mmol/L组	0.36（0.28~0.47）		0.74±0.34	0.12（0.10~0.16）	2.80±0.91
TG 1.00~1.99 mmol/L组	0.47（0.39~0.62）^**		0.96±0.31^***	0.23（0.19~0.30）^***	3.39±0.95^***
TG 2.00~2.99 mmol/L组	0.68（0.52~0.95）^***#		1.25±0.31^***##	0.43（0.38~0.53）^***##	3.88±0.99^***#
TG≥3.00 mmol/L组	1.08（0.78~1.38）^***##△		1.82±0.50^***##△△	0.95（0.71~1.30）^***##△△	4.35±0.85^***##